...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Est. Cash Position

Thanks for all of this information! Not much $$$ here either!

$1.5 million loan and they canceled the reversionary right for Newsoara?

That doesn't sound good! What's your take, given it's non-interest bearing?

Share
New Message
Please login to post a reply